Search - tctmd.com

Displaying 481 - 500 of 1103

Sort: Relevancy | Date

News Daily News

PAD Patients Undertreated With Statins Despite Elevated CV Risk

L.A. McKeown

July 13, 2020

News Daily News

Inflammation Plays Into the ASCVD Risk Associated With Lp(a): ACCELERATE

Michael O'Riordan

July 08, 2020

A secondary analysis from ASPREE sets up two large RCTs testing statins in an elderly primary-prevention population.

News Daily News

Statins Cut CV Risk but Don’t Boost Disability-Free Survival in Healthy Elderly

Michael O'Riordan

July 06, 2020

News Daily News

Rivaroxaban May Yet Protect After a Hospital Stay: MARINER

Caitlin E. Cox

June 25, 2020

News Daily News

Rural-Urban Gap Widens for Cardiometabolic Health Disparities

Michael O'Riordan

June 22, 2020

News Daily News

Most Stable Angina Patients Not Taking First-line Meds

Shelley Wood

June 18, 2020

News Daily News

Hydroxychloroquine Fails to Prevent COVID-19 in Those Exposed to the Virus: RCT

Caitlin E. Cox

June 05, 2020

News Daily News

Lancet COVID-19 Hydroxychloroquine Study Faces ‘Data Integrity’ Questions

Michael O'Riordan

May 29, 2020

News Daily News

Women, Elderly, Minorities Vastly Underrepresented in Clinical Trials Over Decades

Yael L. Maxwell

May 28, 2020

News Daily News

More Evidence of Lower Fracture Risk With DOACs Versus Warfarin

Todd Neale

May 19, 2020

News Daily News

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

Michael O'Riordan

May 15, 2020

News Features

Hospitals Plan Cautious Restart to Elective Procedures as COVID-19 Wanes

Michael O'Riordan

May 12, 2020

News Daily News

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Michael O'Riordan

May 04, 2020

News Features

COVID-19 Lockdown Inactivity May Spell Trouble for CVD Prevention

Michael O'Riordan

April 24, 2020

News Daily News

How COVID-19 Promotes Thrombosis, Posing Problems for Drug-Drug Interactions

Michael O'Riordan

April 22, 2020

News Conference News ACC 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Yael L. Maxwell

April 06, 2020

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Todd Neale

April 02, 2020

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

News Conference News ACC 2020

Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients

L.A. McKeown

April 01, 2020

Hope for these hard-to-treat patients: more than half saw ≥ 50% decrease at 24 weeks, regardless of LDL receptor function.

News Conference News ACC 2020

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Yael L. Maxwell

April 01, 2020

Advertisement

PAD Patients Undertreated With Statins Despite Elevated CV Risk

Inflammation Plays Into the ASCVD Risk Associated With Lp(a): ACCELERATE

Statins Cut CV Risk but Don’t Boost Disability-Free Survival in Healthy Elderly

Rivaroxaban May Yet Protect After a Hospital Stay: MARINER

Rural-Urban Gap Widens for Cardiometabolic Health Disparities

Most Stable Angina Patients Not Taking First-line Meds

Hydroxychloroquine Fails to Prevent COVID-19 in Those Exposed to the Virus: RCT

Lancet COVID-19 Hydroxychloroquine Study Faces ‘Data Integrity’ Questions

Women, Elderly, Minorities Vastly Underrepresented in Clinical Trials Over Decades

More Evidence of Lower Fracture Risk With DOACs Versus Warfarin

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

Hospitals Plan Cautious Restart to Elective Procedures as COVID-19 Wanes

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

COVID-19 Lockdown Inactivity May Spell Trouble for CVD Prevention

How COVID-19 Promotes Thrombosis, Posing Problems for Drug-Drug Interactions

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content